Paul K. Paik, MD

Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.

Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.

An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.

A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.

Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.

An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.

Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.